drug · intermediate · partly written
Fetal tissue transplants for Parkinson disease
Fetal tissue transplants put dopamine-rich midbrain tissue from fetuses into the brain of people with Parkinson disease; two sham-controlled trials missed their main goals and many grafted patients developed involuntary movements.
Also called: fetal nigral transplantation, embryonic dopamine neuron transplants
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What was tried
Developing dopamine-producing neurons from fetal brain tissue were implanted into the putamen of people with severe Parkinson disease. Open trials looked good, but two sham-controlled trials did not show a clear benefit, and many grafted patients developed involuntary movements even when off their medication. 12
Reported, not yet replicated
How the cells were placed more
This one is surgery. In the first trial, cultured mesencephalic tissue from four embryos was implanted into the putamen on both sides; control patients had holes drilled in the skull but the dura was not penetrated. There is no glue: the neurons are meant to survive, send fibres into the host tissue and wire into existing circuits. The trials show that the biology worked in part (fibre outgrowth in 17 of 20 patients; neuron survival at autopsy; higher fluorodopa uptake) and still did not give a clear clinical benefit. 12
Reported, not yet replicated
The two sham-controlled trials in numbers deep
Freed 2001: 40 patients aged 34 to 75, mean disease duration 14 years, randomised to transplant or sham, followed double-blind for one year. Primary outcome (subjective global rating, scale -3 to +3): 0.0 versus -0.4. Younger patients: P=0.01 on the Unified Parkinson Disease Rating Scale and P=0.006 on the Schwab and England score. Dystonia and dyskinesias recurred in 15 percent after the first year.
Olanow 2003: 34 patients, 24-month double-blind placebo-controlled trial, one donor or four donors per side versus a placebo procedure. Off-state motor UPDRS change: the placebo group worsened by 9.4 points, the one-donor group by 3.5, the four-donor group improved by 0.72; no significant overall effect (p=0.244). On stratification a treatment effect was seen in milder patients (p=0.006). 56 percent of transplanted patients developed off-medication dyskinesia. 12
Reported, not yet replicated
Why the grafts caused dyskinesia deep
The best-supported explanation so far is that fetal tissue brings along serotonin neurons: imaging in two patients showed excessive serotonergic innervation in the graft, and a drug that dampens serotonin neuron release attenuated the dyskinesias markedly. A review reports grafts holding serotonin neurons in the order of half the number of dopamine cells. A rat study linked small, single graft deposits and uneven, patchy reinnervation to dyskinesia. These explanations are plausible and partly proven in few cases; they are not settled for every graft.
Separately, a graft examined 14 years after transplantation in one patient had Lewy body-like inclusions in grafted neurons, which suggests the disease can affect new cells too. 3456
Contested
Modality
Targets
Pathways
Indications
Identifiers
Doi freed 2001
10.1056/NEJM200103083441002
Doi olanow 2003
10.1002/ana.10720
Mechanism
Parkinson motor symptoms follow loss of dopamine neurons in the substantia nigra. The idea was to implant developing dopamine neurons from fetal midbrain tissue into the putamen, the striatal region they would normally feed, so that new neurons make dopamine locally. Open trials without a control group looked beneficial. 14
Reported, not yet replicated
Delivery route
Must survive
Surgery through the skull, survival of the grafted neurons, growth of fibres into the host tissue, and the host immune system. The abstracts show survival and fibre growth: fibre outgrowth was detected in 17 of 20 transplanted patients in the first trial, and dopamine neurons survived at autopsy in the second. Whether any immunosuppression was given was not found in the abstracts read; a review lists its absence as a likely contributor to the failures. 124
Reported, not yet replicated
Assays used
Fluorodopa PET
Uptake of 18F-fluorodopa in the striatum rose after transplantation in the second trial, showing the grafted neurons were taking up and making dopamine. 2
Reported, not yet replicated
Sham surgery control
In the first trial, control patients had holes drilled in the skull without penetrating the dura, so patients and assessors stayed blind. 1
Reported, not yet replicated
Side effects
Off-medication dyskinesia (graft-induced dyskinesia)
In the first trial, dystonia and dyskinesias recurred in 15 percent of transplanted patients after the first year, even after levodopa was reduced or stopped. In the second trial 56 percent of transplanted patients developed dyskinesia that persisted after overnight withdrawal of dopaminergic medication. 12
Reported, not yet replicated
Verdict
Outcome
failed
Why
Open-label trials were encouraging, but the two double-blind sham-controlled trials did not show a clear benefit. In the first (40 patients, tissue from four embryos per patient), the global rating at one year was 0.0 (SD 2.1) with transplant against -0.4 (SD 1.7) with sham; younger patients (60 or under) improved on morning-off motor tests (P=0.01), older ones did not. In the second (34 patients, 24 months), the primary endpoint, change in off-state motor score, showed no significant overall treatment effect (p=0.244; four donors versus placebo p=0.096). The authors concluded fetal nigral transplantation cannot currently be recommended as a therapy. No product was approved. 12
Reported, not yet replicated
Failure mode
The cells survived, so engraftment was not the failure. The grafts did not reliably improve the disease and caused off-medication dyskinesia in a large share of patients. Candidate explanations, none proven for all grafts: (1) serotonin neurons, which fetal tissue contains: in two patients imaging showed excessive serotonergic innervation of the graft and a 5-HT1A agonist markedly reduced the dyskinesias, and a review puts graft serotonin neurons at about half the number of dopamine cells; (2) uneven, patchy reinnervation from small graft deposits, shown in rats; (3) lack of standardised tissue and of post-surgical immunosuppression, which the field review gives as the general view of what contributed to the trials failing; (4) in one patient, Lewy body-like inclusions appeared in the grafted neurons 14 years later, so the disease process can reach the new cells. 3456
Contested
Teach this
In one sentence
Fetal dopamine neurons survived in the brain and still failed, because living cells are not the same as a working, well-patterned circuit. 23
Reported, not yet replicated
The five-minute version
Idea: replace lost dopamine neurons. Open trials looked good. Two sham-controlled trials did not: primary endpoints were missed, neurons survived, and 15 and 56 percent of grafted patients had dyskinesia. Mixed tissue (serotonin neurons), patchy placement and non-standard tissue are the leading explanations. Lesson: ask separately whether cells survive, function, and are tolerated. 124
Reported, not yet replicated
What a listener will ask
Was it rejected?
Survival was shown at autopsy, so rejection is not what the abstracts report; whether immunosuppression was used was not found, and a review lists its absence as a possible contributor.
Why believe the sham trials over the open ones?
Open trials have no control for placebo effects; the sham-controlled trials did, and also exposed dyskinesia that the open ones had not.
The common wrong idea
If the transplanted cells survive, the therapy has worked.
Survival is necessary but not sufficient: the grafts survived and still missed the primary endpoint and caused dyskinesia.
The one citation to hand over: 2
Still open here
- Did either trial use immunosuppression, and with what regimen? Only abstracts were read.
- Which explanation of graft-induced dyskinesia holds across patients? Evidence is two patients (serotonin) and rat work (placement).
- Do defined, stem-cell-derived dopamine neurons avoid the problem? Not covered by the sources opened here.
Not yet written: Off targets.
Linked from
Sources
- Freed, C. R., Greene, P. E., Breeze, R. E., et al.. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine (2001). paper; opened 2026-11-17 all records citing this
- Olanow, C. W., Goetz, C. G., Kordower, J. H., et al.. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology (2003). paper; opened 2026-11-17 all records citing this
- Politis, M., Wu, K., Loane, C., et al.. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Science Translational Medicine (2010). paper; opened 2026-11-17 all records citing this
- Tronci, E., Fidalgo, C., Carta, M.. Foetal cell transplantation for Parkinson's disease: focus on graft-induced dyskinesia. Parkinson's Disease (2015). review; opened 2026-11-17 all records citing this
- Carlsson, T., Winkler, C., Lundblad, M., et al.. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease (2006). paper; opened 2026-11-17 all records citing this
- Kordower, J. H., Chu, Y., Hauser, R. A., et al.. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine (2008). paper; opened 2026-11-17 all records citing this
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2001
- Regulatory status
- failed-in-trials
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/drugs/fetal-tissue-parkinson-transplants.json